Deregulation of AKT-mTOR signaling has been found in most cancers and the mTOR axis is a common target for the development of molecular targeted therapies for cancer [18, 20], however, whether RNR is regulated by mTOR in mammalian cells and deregulation of RNR contributes to the carcinogenesis and anti-cancer drug resistance by mTOR signaling is unknown. The gene discussed is NR2E3; the disease is cancer.